Skip to main content
. Author manuscript; available in PMC: 2015 Sep 15.
Published in final edited form as: Cancer Res. 2014 Aug 18;74(18):5152–5164. doi: 10.1158/0008-5472.CAN-14-0294

Figure 6. AXL is overexpressed and activated in cetuximab resistant HNSCC PDXs.

Figure 6

PDXs were evaluated for cetuximab response as described in the supplemental materials and methods. Tumor growth was plotted as a percentage of averaged vehicle treated tumor volumes at the last three time points of the study; *p<0.05, **p<0.01. Representative images of IHC analysis of AXL and pAXL-Y779 staining in early passaged PDXs are shown (20X). Quantitation of IHC was performed via Image J software (average of 2-5 independent tumors were stained and imaged); values were normalized to the average staining of UW-SCC36.